Back to Clinical Trials
N/ARecruiting

Rare and Atypical Diabetes Network

Sponsored by University of South Florida

About this study

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.

RADIANT has three distinct stages. Stage 1: Stage 1 participants will complete a consent form and a questionnaire to determine the potential for having atypical forms of diabetes. Participants identified as potentially atypical based on questionnaire responses will be asked to provide a blood sample to test for islet autoantibodies and complete additional questionnaires. The RADIANT Adjudication Committee, which is comprised of a team of experts in diabetes, will assess the data collected in Stage 1 and select and prioritize participants to proceed to Stage 2 and 3 for Whole Genome Sequencing (WGS) and other testing. Stage 2: Stage 2 of the study includes genetic screening for known forms of monogenic diabetes. Participants will consent for this stage of the study, complete a family h…

Where this study is enrolling (13)

Show all 13 locations
Who can participate

Inclusion criteria

  • ✓The following criteria or phenotypes will be considered for suspecting "atypical" participants:
  • ✓Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese
  • ✓Mendelian pattern, especially with early onset (\<18 years old)
  • ✓Syndromic (multiple systems involved)
  • ✓Lipodystrophic
  • ✓Extremes of BMI
  • ✓"Mitochondrial" characteristics (e.g., myopathy, hearing deficits)
  • ✓Non-progressive
  • ✓Rapidly progressive ("fulminant")
  • ✓Low insulin requirements (\<0.5 u/kg/day)
  • ✓Cyclical hyperglycemia with periods of remission
  • ✓Lean persons with polycystic ovarian syndrome (PCOS)
  • ✓History of gestational diabetes (GDM) when lean
  • ✓Lean insulin-resistant persons
  • ✓If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function):
  • ✓oA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype)

Exclusion criteria

  • ✕Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes
  • ✕Refusal of consent for genetic testing
  • ✕Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)
  • ✕Women who are currently pregnant

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.